1xbet 모바일 Pharmaceutical Co., Ltd.

• Innovative public-private partnership opens access to delamanid for the treatment of multidrug-resistant tuberculosis (MDR-1xbet 모바일) to more than 100 countries that may procure anti-1xbet 모바일 medications through GDF
• Agreement includes package of services and technical assistance 1xbet 모바일 help countries incorporate delamanid in1xbet 모바일 their existing treatment programmes
• MDR-1xbet 모바일 remains a major global health concern with 480,000 people infected each year and only a 50% treatment success rate^*1

Recognizing the immediate need for access to new therapeutic options for multidrug-resistant 1xbet 모바일 (MDR-1xbet 모바일), Otsuka Pharmaceutical Co., Ltd.'s subsidiary Otsuka Novel Products GmbH today announced an ambitious new public-private partnership with the Stop 1xbet 모바일 Partnership (Stop 1xbet 모바일) to increase access and scale-up treatment of delamanid (Deltyba^™) in low- and middle-income countries.

Any country that is eligible for 1xbet 모바일 financing from the Global Fund to Fight AIDS, 1xbet 모바일 and Malaria and follows World Health Organization (WHO) guidelines for the proper management of MDR-1xbet 모바일 in quality-assured programs may apply to Stop 1xbet 모바일's Global Drug Facility (GDF) to incorporate delamanid into their national treatment programmes. It is estimated that more than 100 countries may now be eligible to access delamanid through the GDF.

"This agreement with the Stop 1xbet 모바일 Partnership is only the first step in assuring wider, equitable access to delamanid," said Masuhiro Yoshitake, executive operating officer of Otsuka and 1xbet 모바일 Global Project leader. "Otsuka is committed to working with all stakeholders in the 1xbet 모바일 community to scale-up delamanid use in a rational way that supports larger efforts to combat antimicrobial resistance."

"Our goal is to ensure all people with 1xbet 모바일 have access to the best possible treatment. Until now, delamanid was not available for procurement in low- and middle-income countries. We are hopeful that this partnership is going to help give countries more tools and more options to fight MDR-1xbet 모바일 in their communities," said Dr Lucica Ditiu, executive director of the Stop 1xbet 모바일 Partnership.

By establishing a formalized partnership that goes beyond the supply of medicine, Otsuka and Stop 1xbet 모바일 will work more closely to support communities with education, training, technical assistance, and 1xbet 모바일 advocacy activities.

This partnership is only one component of Otsuka's "Figh1xbet 모바일ack Initiative" which incorporates innovative research and development, collaborative capacity building, responsible access to patients and optimised patient management. Beyond delamanid, the initiative includes the development of a first-ever paediatric formulation for MDR-1xbet 모바일, diagnostic solutions, mHealth tools, and potential future anti-1xbet 모바일 drug candidates. Otsuka is also engaging in close to a dozen third-party research collaborations looking at shorter, more effective and more patient-friendly ways to fight MDR-1xbet 모바일. Included in this, Otsuka is proud to work with Médecins Sans Frontières, Partners in Health and Interactive Research & Development on the end1xbet 모바일 project which will evaluate new regimens for the treatment of MDR-1xbet 모바일 and reduce existing country-level barriers to the uptake of new 1xbet 모바일 drugs while building a broader evidence-base for WHO recommendations.

1. 1World Health Organization. Global Tuberculosis Report 2015. Geneva, Switzerland. WHO/HTM/1xbet 모바일/2015.22
2. 2World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis - interim policy guidance. 2014, Geneva, Switzerland. WHO/HTM/1xbet 모바일2014.23